Decades of research have characterized diverse immune cells surveilling the CNS. More
recently, the discovery of osseous channels (so-called 'skull channels') connecting the …

The era of genomic medicine has allowed acute myeloid leukemia (AML) researchers to
improve disease characterization, optimize risk-stratification systems, and develop new …

Inter-patient variability and the similarity of healthy and leukemic stem cells (LSCs) have
impeded the characterization of LSCs in acute myeloid leukemia (AML) and their …

The BCL2 inhibitor venetoclax has recently emerged as an important component of acute
myeloid leukemia (AML) therapy. Notably, use of this agent has revealed a previously …

Background Third-generation chimeric antigen receptor (CAR)-engineered T cells (CARTs)
might improve clinical outcome of patients with B cell malignancies. This is the first report on …

In BCR-ABL1 lymphoblastic leukemia, treatment heterogeneity to tyrosine kinase inhibitors
(TKIs), especially in the absence of kinase domain mutations in BCR-ABL1, is poorly …

Hematopoiesis is regulated by the bone marrow (BM) stroma. However, cellular identities
and functions of the different BM stromal elements in humans remain poorly defined. Based …

High-risk childhood leukemia has a poor prognosis because of treatment failure and toxic
side effects of therapy. Drug encapsulation into liposomal nanocarriers has shown clinical …

Multimodal single-cell technologies profile multiple modalities for each cell simultaneously,
enabling a more thorough characterization of cell populations. Existing dimension-reduction …

Acute myeloid leukemia (AML) is a hematological malignancy derived from neoplastic
myeloid progenitor cells characterized by abnormal clonal proliferation and differentiation …